Pfizer Inc. $PFE Shares Bought by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 85.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,251 shares of the biopharmaceutical company’s stock after buying an additional 20,858 shares during the quarter. Elevated Capital Advisors LLC’s holdings in Pfizer were worth $1,271,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. Norges Bank acquired a new position in shares of Pfizer in the 4th quarter worth approximately $1,830,986,000. Morgan Stanley increased its holdings in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp raised its position in Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Franklin Resources Inc. raised its position in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after purchasing an additional 7,489,189 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited as AstraZeneca’s failed Phase 3 trial in a rare heart disease pushed investors toward rival drugmakers, including PFE. Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
• Positive Sentiment: Pfizer’s oncology franchise got some attention after reports suggesting recent FDA action on IBRANCE could improve the investment case for the company’s cancer portfolio. Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?
• Positive Sentiment: Pfizer also highlighted ongoing pipeline work, including a Phase 1 bioavailability study and its MUST multiple myeloma study, reinforcing the company’s longer-term R&D pipeline narrative. Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study Pfizer’s MUST Study Offers Fresh Insight Into Tough‑to‑Treat Multiple Myeloma
• Neutral Sentiment: J.P. Morgan lowered its price target on Pfizer and kept a Neutral rating, which signals continued caution even though the firm still sees some upside from current levels. Pfizer (PFE) Receives a Hold from J.P. Morgan
• Neutral Sentiment: Additional headlines around Pfizer’s dividend appeal, valuation, and analyst commentary are likely reinforcing investor debate, but they do not point to a major fundamental shift by themselves. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Jim Cramer declined to recommend Pfizer despite its high dividend yield, reflecting ongoing skepticism about the stock’s near-term appeal. ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wolfe Research restated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Guggenheim boosted their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Monday. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.56.

Pfizer Price Performance

PFE stock opened at $24.22 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market capitalization of $138.02 billion, a P/E ratio of 18.49 and a beta of 0.35. The business’s 50-day moving average is $25.41 and its two-hundred day moving average is $26.20. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the business posted $0.92 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer’s payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.